Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Esperion Therapeutics Inc (ESPR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Esperion's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.87 +0.03    +1.63%
18/04 - Closed. Currency in USD ( Disclaimer )
After Hours
1.84
-0.03
-1.60%
19:54:22 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 5,909,114
  • Bid/Ask: 1.84 / 1.89
  • Day's Range: 1.81 - 2.03
Esperion 1.87 +0.03 +1.63%

Esperion Therapeutics Inc Company Profile

 
Get an in-depth profile of Esperion Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

-

Equity Type

ORD

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Contact Information

Address 3891 Ranchero Drive Suite 150
Ann Arbor, 48108
United States
Phone 734 887 3903
Fax -

Top Executives

Name Age Since Title
Daniel S. Janney 56 2012 Independent Director
Nicole Vitullo 65 2008 Lead Independent Director
Antonio M. Gotto 87 2014 Independent Director
Sheldon L. Koenig 56 2020 President, CEO & Director
Seth H. Z. Fischer 66 2021 Independent Director
Alan Fuhrman 65 2020 Independent Non-Employee Director
J. Martin Carroll 74 2022 Independent Chairperson
Stephen Charles Rocamboli 51 2022 Independent Director
Karin Bornfeldt - 2022 Member of Scientific Advisory Board
Tracy M. Woody 53 2019 Independent Director
Jay P. Shepard 65 2018 Independent Director
Erin A. Bohula - 2022 Member of Scientific Advisory Board
Gerald I. Shulman - 2022 Member of Scientific Advisory Board
R. Preston Mason - 2022 Member of Scientific Advisory Board
Dennis Bruemmer - 2022 Member of Scientific Advisory Board
Marilyn Glassberg - 2022 Member of Scientific Advisory Board
Peter Libby 76 2022 Member of Scientific Advisory Board
Pradeep Natarajan - 2022 Member of Scientific Advisory Board
David E. Cohen - 2022 Member of Scientific Advisory Board
Jeffrey Bender - 2022 Member of Scientific Advisory Board
Gabrielle Fredman - 2022 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ESPR Comments

Write your thoughts about Esperion Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Seghyus Obywan
Seghyus Obywan Apr 11, 2024 10:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
p o r c k o d j i o ?
Seghyus Obywan
Seghyus Obywan Apr 10, 2024 12:53PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
opinions on this strange drop down?
Chris Clark
Chris Clark Apr 08, 2024 12:10PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
why would some dumas short this stock? control freek
Count da Money
CountdaMoney Mar 22, 2024 10:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
And boom! FDA approval makes it wirth 2,3, 5x??
Merter Ortac
Merter Ortac Jan 03, 2024 10:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Wtf.
Gregory Vengrin
Gregory Vengrin Jul 13, 2023 7:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Ready to POP. . Load up. .
Dmitry Vl
Dmitry Vl Jan 07, 2022 9:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
still waiting for 40$ is it possible this year?
Michael Vaynagiy
Michael Vaynagiy Jan 07, 2022 9:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I think 20$ is hardly possible this year.
Ted Alfonsetti III
Ted Alfonsetti III Dec 03, 2021 9:58AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Does anyone look at even the financials? This company is a dumpster fire, and the dumpster is full of cash and debt.
Piter Pen
Piter Pen Dec 03, 2021 6:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pre Market prise, what happened?
Marco Bertozzi
Marco Bertozzi Oct 07, 2021 5:34AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$ 10.17 seems to me a good opportunity for range-bounds traders.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email